Lotus Pharmaceutical 

TWD261.5
0
+TWD1.5+0.58% 今天

统计数据

当日最高
262.5
当日最低
259.5
52周最高
347
52周最低
205
成交量
318,855
平均成交量
2,187,418
市值
68.7B
市盈率
16.56
股息收益率
1.79%
股息
4.67

即将到来

股息

1.79%股息收益率
10年增长
N/A
5年增长
N/A
3年增长
136.8%
1年增长
N/A

收益

7Nov预期
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
下一个
1.52
3.06
4.61
6.15
预期每股收益
6.153453121603551
实际每股收益
N/A

人们还关注

此列表基于关注1795.TW的Stock Events用户的观察列表。这不是投资建议。

竞争者

这个列表是基于最近市场事件的分析。这不是投资建议。

关于

Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, cardiology, nephrology, women's health, anti-obesity, and central nervous system diseases. The company also provides over-the-counter products. In addition, it engages in retail of clinical machines; biotech technological consulting services; sale of pharmaceuticals and medicinal chemical products; marketing activities; market planning and business information services; and consultancy services on health management, health technology, and trading information services. Further, the company offers management consultancy services; pharmaceutical regulatory affairs project management, and data collection and agency services; healthcare consultancy services and operates as a contract research organization. The company has strategic partnership with NRX Pharmaceuticals. Lotus Pharmaceutical Co., Ltd. was incorporated in 1966 and is headquartered in Taipei City, Taiwan.
Show more...
首席执行官
Mr. Petar Antonov Vazharov
国家
TW
ISIN
TW0001795003

上市公司